16th April 2018

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

The Company wishes to inform you that the US FDA conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility from 2nd April 2018 till 13th April 2018. This was in the normal course of business. There were no data integrity and/or repeat observations. At this stage, the Company believes the observations are unlikely to have any material adverse impact. The Company will submit the response within the stipulated timeframe.

Thank you,

Yours faithfully,
For Cipla Limited

Kedar Upadhye
Global Chief Financial Officer